Related Experiment Video

Updated: Aug 14, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Increased Bcl2 expression by antisense oligoribonucleotides targeting the adenine-uridine-rich element motif

Laura Ghisolfi1, Laura Papucci, Annamaria Bevilacqua

  • 1Department of Pharmacology, University of Milan, Via Vanvitelli 32, 20129 Milan, Italy.

Molecular Pharmacology
|June 16, 2005
PubMed

Insights

This study demonstrates a novel method to increase messenger RNA (mRNA) expression by stabilizing specific RNA structures. Antisense oligoribonucleotides (asORNs) were used to up-regulate bcl2 RNA, offering new therapeutic strategies.

Area of Science:

  • Molecular Biology
  • Pharmacology
  • RNA Therapeutics

Background:

  • Messenger RNA (mRNA) is a key target for pharmacological intervention.
  • Current strategies primarily focus on down-regulating mRNA function.
  • Sequence-specific up-regulation of mRNA presents a novel therapeutic avenue.

Purpose of the Study:

  • To investigate the sequence-specific up-regulation of messenger RNA (mRNA).
  • To target the bcl2 adenine-uridine-rich element (b-ARE) in b-RNA using antisense oligoribonucleotides (asORNs).
  • To evaluate the efficacy of asORNs in stabilizing b-RNA and increasing its expression.

Main Methods:

  • Design and synthesis of three chemically modified antisense oligoribonucleotides (asORNs).
  • Cell-free RNA degradation assays to assess RNA decay rates.
  • Transfection of asORNs into malignant cells and measurement of b-RNA half-life using real-time RT-PCR.

Main Results:

  • All three asORNs demonstrated dose-dependent inhibition of b-RNA decay.
  • The asORNs showed specificity for the b-ARE.
  • Two asORNs were individually effective in stabilizing b-RNA.
  • Transfected asORNs led to increased b-RNA and relevant protein expression in a dose-dependent manner.

Conclusions:

  • Antisense oligoribonucleotides can effectively stabilize b-RNA by targeting the b-ARE.
  • This stabilization leads to sequence-specific up-regulation of b-RNA and protein expression.
  • The findings support a new strategy for RNA-based therapeutics focused on up-regulation.

More Related Videos

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells11:11

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells

Published on: April 25, 2018

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction06:01

Expression of Transgenes in Native Bladder Urothelium Using Adenovirus-Mediated Transduction

Published on: October 6, 2022

Related Concept Videos

Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...